tirzepatide phase 2 obesity Frontiers Tirzepatide: First Approval | Drugs
Description
Fibrosis improvement occurred in 43% of semaglutide-treated patients versus 33% with placebo, though this difference was not statistically significant
Your PlexusDx provider monitors your tolerance and adjusts your treatment plan accordingly
2016;129(4):407-415.e404
However, regaining weight after the surgery is common and can exacerbate obesity-related conditions such as Type 2 diabetes and fatty liver disease
(Lomeli et al., 2017
Neuron 23, 775786
